Browsing Tag
Suzhou Ribo Life Science Co.
1 post
Ribo enters obesity RNAi race as RBD3133 moves toward first human study in Europe
Suzhou Ribo Life Science has filed for a European Phase I trial of RBD3133, taking its first obesity candidate toward human testing as multiple RNAi developers pursue INHBE as a potential fat-selective alternative or complement to incretin therapies.